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Key Points 38 
Question: What is the relationship between hippocampal glutamate levels in people at 39 
clinical high risk (CHR) for psychosis and subsequent clinical outcomes? 40 
Findings: This cross-sectional 3-Tesla proton magnetic resonance spectroscopy (1H-MRS) 41 
study with a mean clinical follow-up of 18.5 months shows that baseline hippocampal 42 
glutamate levels are significantly higher in those CHR subjects who developed psychosis or 43 
had poor functional outcome at follow up. 44 
Meaning: This association between adverse clinical outcomes in people at CHR for 45 
psychosis and increased baseline hippocampal glutamate levels suggests that these 46 
measures could contribute to the stratification of CHR subjects according to future clinical 47 
outcomes. 48 
  49 
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Abstract 50 
Importance: Preclinical and human data suggest that hippocampal dysfunction plays a 51 
critical role in the onset of psychosis. Neural hyperactivity in the hippocampus is thought to 52 
drive an increase in subcortical dopamine function through glutamatergic projections to the 53 
striatum. 54 
Objective: To examine the relationship between hippocampal glutamate levels in people at 55 
clinical high risk (CHR) for psychosis and subsequent clinical outcomes. 56 
Design: Cross-sectional 3-Tesla proton magnetic resonance spectroscopy (1H-MRS) study 57 
with a mean subsequent clinical follow up of 18.5 months, conducted between November 58 
2011 and November 2017.   59 
Setting: Early detection services for CHR individuals in London and Cambridge.  60 
Participants: 86 individuals at CHR for psychosis as defined using the Comprehensive 61 
Assessment of the At-Risk Mental State (CAARMS) and 30 healthy controls.    62 
Main Outcomes and Measures: Concentrations of glutamate and other metabolites were 63 
measured in the left hippocampus at first clinical presentation. At follow up, clinical outcomes 64 
were assessed in terms of transition/non-transition to psychosis (CAARMS criteria) and the 65 
level of overall functioning (Global Assessment of Function scale; GAF). 66 
Results: The mean (SD) age of participants was 22.4 (3.5) years in 86 CHR subjects (50 67 
male) and 24.7 (3.8) years in 30 healthy controls (14 male). At follow up, 12 CHR subjects 68 
developed a first episode of psychosis and 74 CHR subjects did not; 19 CHR subjects 69 
showed good overall functioning (GAF≥65), whereas 38 CHR subjects had a poor functional 70 
outcome (GAF<65). Compared to CHR subjects who did not become psychotic, CHR 71 
subjects who developed psychosis showed higher hippocampal glutamate levels (p=0.048). 72 
They also had higher myo-inositol and creatine levels compared to CHR subjects who did 73 
not become psychotic (p=0.002 and p=0.009, respectively), and higher myo-inositol levels 74 
than HCs (p=0.005). Higher hippocampal glutamate levels in CHR subjects were also 75 
associated with a poor functional outcome (p = 0.015).  76 
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Conclusions and Relevance: These findings indicate that adverse clinical outcomes in 77 
people at CHR for psychosis are associated with an increase in baseline hippocampal 78 
glutamate levels, as well as in myo-inositol and creatine levels. This suggests that these 79 
measures could contribute to the stratification of CHR subjects according to future clinical 80 
outcomes. 81 
 82 
 83 
  84 
6 
 
Introduction 85 
Both preclinical and human studies suggest that hippocampal dysfunction plays a 86 
critical role in the onset of psychosis. Data from animal models indicate that neural 87 
hyperactivity in the hippocampus drives an increase in subcortical dopamine function 88 
through glutamatergic projections to the striatum.1,2 Neuroimaging studies in people at 89 
Clinical High Risk (CHR) for psychosis suggest that the subsequent onset of psychosis is 90 
associated with changes in several measures of hippocampal integrity, including 91 
hypermetabolism,3 increased resting perfusion,4 altered activation in response to cognitive 92 
tasks,5 and reduced grey matter volume.3,6,7 The mechanisms underlying these changes are 93 
unclear, but experimental work in rodents suggests that they may be secondary to increases 94 
in hippocampal glutamate levels.3  95 
A large body of independent research suggests that psychosis involves alterations in 96 
glutamate neurotransmission.8,9 For example, non-competitive N-methyl-D-aspartate 97 
(NMDA) receptor antagonists such as ketamine and phencyclidine can induce psychotic 98 
symptoms in healthy individuals,10,11 and exacerbate psychotic symptoms in patients with a 99 
psychotic disorder.12,13 In addition, autoantibodies to the NMDA receptor are present in a 100 
proportion of patients with psychosis,14,15 and several risk genes associated with psychosis 101 
code for proteins involved in glutamatergic neurotransmission.16   102 
Brain glutamate levels can be measured in vivo using Proton Magnetic Resonance 103 
Spectroscopy (1H-MRS). A meta-analysis on levels of glutamatergic metabolites in patients 104 
with psychosis suggests that there are elevations in several brain regions, including 105 
increased concentrations of Glx (the combined measure of glutamine and glutamate) in the 106 
medial temporal lobe.17 The few 1H-MRS studies that examined  hippocampal glutamate in 107 
CHR subjects did not find differences relative to healthy controls,18-20 but they did not 108 
investigate hippocampal glutamate concentrations in relation to clinical outcomes. However, 109 
relationships between glutamate levels and adverse outcomes in CHR subjects have been 110 
identified in 1H-MRS studies of other brain regions. De la Fuente Sandoval and colleagues 111 
found that glutamate levels in the striatum were elevated in CHR subjects who developed 112 
7 
 
psychosis subsequent to scanning, but not in CHR subjects who did not.21 Furthermore, in 113 
the thalamus, low baseline glutamate levels were associated with poor functioning at clinical 114 
follow up,22 and with a failure to achieve symptomatic remission from the CHR state.23 115 
The primary aim of the present study was to investigate the relationship between 116 
hippocampal glutamate levels in CHR subjects and subsequent clinical outcomes. We used 117 
1H-MRS to examine a sample of CHR subjects and a group of healthy volunteers. CHR 118 
subjects were then followed up to determine their clinical outcomes, which were assessed in 119 
terms of transition/non-transition to psychosis and level of overall functioning. Our primary 120 
hypothesis was that in CHR subjects, elevated hippocampal glutamate levels at baseline 121 
would be associated with adverse clinical outcomes: the onset of psychosis and a low level 122 
of overall functioning. In view of the evidence of a more general disruption of hippocampal 123 
function prior to the onset of psychosis, we also explored the relationship between clinical 124 
outcomes and levels of other hippocampal metabolites. 125 
  126 
  127 
 128 
 129 
  130 
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Materials and Methods 131 
 132 
Participants  133 
A total of 116 participants took part in the study. The study had National Health Service 134 
UK Research Ethics Committee (coREC) approval, and all participants gave written 135 
informed consent before taking part.  136 
CHR subjects (n = 86) were recruited via early detection services for people at CHR for 137 
psychosis: Outreach and Support in South London (OASIS), the West London Early 138 
Intervention service, and Cambridge Early Onset service (CAMEO).24 The diagnosis was 139 
made using the Comprehensive Assessment of the At-Risk Mental State (CAARMS).25 140 
Subjects met one or more of the following criteria: (a) attenuated psychotic symptoms, (b) 141 
brief limited intermittent psychotic symptoms (a history of one or more episodes of frank 142 
psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) a 143 
recent decline in function, together with either the presence of schizotypal personality 144 
disorder or a family history of psychosis in a first-degree relative.  145 
Healthy controls (HC, n=30) were recruited from the local community. All were native 146 
English speakers, had no history of psychiatric disorder and none were using prescription 147 
medication.  148 
     On the day of scanning, symptomatology was assessed using the CAARMS.26 149 
Psychosocial functioning was examined with the Global Assessment of Function (GAF) 150 
scale,26 and measures of anxiety and depression were obtained using the Hamilton rating 151 
scales (HAM-A and HAM-D, respectively).27,28 Pre-morbid IQ was assessed with the National 152 
Adult Reading Test (NART),29 and handedness was determined using the Annett 153 
Handedness Scale.30 Subjects provided information on tobacco use (cigarettes per day) and 154 
cannabis use (0=no use, 1=experimental use, 2=occasional use, 3=moderate use, 4=severe 155 
use). Participants were excluded if they reported illicit substance use in the week prior to 156 
scanning or alcohol use in the 24 hours prior to scanning, if they met DSM-IV criteria for a 157 
9 
 
substance misuse or dependence disorder, or had a history of neurological or prior psychotic 158 
disorders.  159 
 160 
Clinical follow up 161 
The CHR sample was followed up to determine clinical outcomes. Fifty-seven subjects 162 
underwent a face-to-face clinical re-assessment. The mean interval between the baseline 163 
and follow up assessments was 18.5 months (SD= 9.6 months; range 4 - 59 months). 164 
Clinical outcome was assessed as a) transition/non-transition to psychosis defined using the 165 
criteria in the CAARMS,25 and b) the level of overall functioning determined using the GAF 166 
scale. A minority of the CHR sample could not be re-interviewed (n=29), either because they 167 
were too unwell, declined to be seen, or were uncontactable. In these cases, transition to 168 
psychosis was determined from information in their clinical records, but it was not possible to 169 
rate their overall functioning.  170 
 171 
1H-Magnetic Resonance Spectroscopy 172 
Images were obtained on a General Electric (Milwaukee, Wisconsin) 3.0 Tesla HDx MR 173 
system. 1H-MRS spectra (PRESS - Point RESolved Spectroscopy; TE = 30 ms; TR = 3000 174 
ms; 96 averages) were acquired in the left hippocampus (Figure 1).19 We employed the 175 
standard GE probe (proton brain examination) sequence, which uses a standardised 176 
chemically selective suppression (CHESS) water suppression routine. For each metabolite 177 
spectrum, unsuppressed water reference spectra (16 averages) were also acquired as part 178 
of the standard acquisition. Shimming and water suppression were optimised, with auto-179 
prescan performed twice before each scan. Using standardized protocols, the hippocampal 180 
voxel  (20x20x15 mm; right-left, anterior-posterior, superior-inferior) was prescribed from the 181 
structural T1 scan.  182 
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 183 
Structural Magnetic Resonance Imaging 184 
Structural images were acquired in the same session using a whole-brain three-185 
dimensional sagittal T1-weighted scan, with parameters based on the Alzheimer’s Disease 186 
Neuroimaging Initiative (ADNI) (TE = 2.85 ms; TR = 6.98 ms; inversion time = 400 ms; flip 187 
angle = 11º; voxel size 1.0x1.0x1.2 mm; for full details see 188 
http://adni.loni.usc.edu/methods/mri-analysis/mri-acquisition/). Structural T1 images were 189 
segmented into grey matter, white matter, and cerebrospinal fluid (CSF) using Statistical 190 
Parametric Mapping software (SPM8; Wellcome Trust Centre for Neuroimaging, London, 191 
UK) to allow correction of the 1H-MRS data for partial volume CSF contamination.              192 
  193 
1H-MRS Data Processing 194 
All spectra were analysed with LCModel version 6.3-0A31 using a standard basis set of 16 195 
metabolites (L-alanine, aspartate, creatine, phosphocreatine, GABA, glucose, glutamine, 196 
glutamate, glycerophosphocholine (choline), glycine, myo-inositol, L-lactate, N-197 
acetylaspartate (NAA), N-acetylaspartylglutamate, phosphocholine, and taurine), acquired 198 
with the same field strength (3 Tesla), localisation sequence (PRESS), and echo time (30 199 
ms). Model metabolites and concentrations used in the basis set are fully detailed in the 200 
LCModel manual (http://s-provencher-.com/pages/lcmmanual.shtml). Poorly fitted metabolite 201 
peaks (Cramer-Rao minimum variance bounds of >20% as reported by LCModel) were 202 
excluded from further analysis, and water-scaled glutamate, Glx, myo-inositol, creatine, 203 
choline and NAA values were corrected for voxel tissue composition (see Supplementary 204 
Methods). See for scan quality parameters and voxel tissue composition Supplementary 205 
Tables 1 - 3.   206 
 207 
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Statistics 208 
Group differences in clinical and demographic variables were assessed using two-sample 209 
t-tests or chi-squared tests. To examine the relationship between metabolite levels and 210 
clinical outcomes, the CHR sample was dichotomised according to: a) transition vs. non-211 
transition to psychosis25 and b) good overall functioning (GAF≥65) vs. poor overall 212 
functioning (GAF<65) at follow-up.22 As the primary hypothesis related to the relationship 213 
between hippocampal glutamate levels and clinical outcomes, general linear models were 214 
used to identify group differences in glutamate levels between the respective CHR 215 
subgroups and healthy controls, as well as between the total CHR group and controls. 216 
Glutamate concentrations were included as the dependent variable with group as the 217 
independent variable (p<0.05 considered statistically significant). Concentrations of other 218 
metabolites (Glx, myo-inositol, creatine, choline and NAA) were also assessed in exploratory 219 
general linear models, and were corrected for multiple comparisons (thresholded p < 0.05/5 220 
= 0.01). Multiple regression analyses were performed to examine how hippocampal 221 
glutamate levels predicted clinical outcomes. Age and tobacco consumption were included 222 
as covariates in all analyses because both can influence neurometabolite levels.32,33 All 223 
analyses were performed in SPSS 22. Effect sizes are reported as Hedges’ g.    224 
  225 
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Results 226 
 227 
Demographic, clinical and medication data  228 
All CHR participants (n=86) met the Attenuated Psychotic Symptoms diagnostic criteria, 229 
with some also fulfilling the BLIPS (n=5) or schizotypy / familial risk criteria (n=2). At the time 230 
of scanning, the majority of the CHR sample were antipsychotic naive (72/86). Ten CHR 231 
subjects were receiving low doses of antipsychotic medication (less than 1.5 mg haloperidol 232 
equivalents per day).  233 
The CHR and HC groups did not differ significantly in terms of gender, handedness, IQ or 234 
cannabis use. However, the CHR group was younger, had fewer years of education, and 235 
smoked more cigarettes. As expected, they also had higher HAM-A and HAM-D scores and 236 
lower levels of functioning at baseline compared to controls (see Table 1 and Supplementary 237 
Tables 4 and 5).  238 
At follow up, 12 CHR subjects developed a first episode of psychosis (CHR-Transition, 239 
CHR-T) and 74 CHR subjects did not (CHR-Non-Transition, CHR-NT). When dichotomised 240 
according to their GAF scores, 19 CHR subjects showed a good overall functioning 241 
(GAF≥65; CHR-Good Outcome, CHR-GO), whereas 38 CHR subjects had a poor functional 242 
outcome (GAF<65; CHR-Poor Outcome, CHR-PO).   243 
The CHR-T group had higher baseline HAM-A and HAM-D scores than the CHR-NT 244 
group, but there were no other significant differences in symptom ratings or demographic 245 
measures between these subgroups. There were no significant differences at baseline in 246 
any clinical or demographic measure between the CHR-GO and CHR-PO subgroups (see 247 
Table 1 and Supplementary Tables 4 and 5).  248 
 249 
 250 
 251 
 252 
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Hippocampal metabolite differences  253 
 254 
Transition to psychosis  255 
The CHR-T subgroup had significantly higher hippocampal glutamate levels than the 256 
CHR-NT subgroup (F3,81=4.03, p=0.048; effect size 0.57), and there was a trend for higher 257 
glutamate levels relative to HCs (F3,38=3.54, p=0.07; effect size 0.73). There was no 258 
difference in glutamate levels between the CHR-NT and HC groups (Figure 2).  259 
Exploratory testing revealed that the CHR-T subjects also had significantly higher 260 
hippocampal myo-inositol and creatine levels than the CHR-NT subjects (F3,81=10.26, 261 
p=0.002 and F3,82=7.26, p=0.009, respectively), and higher myo-inositol levels than the HCs 262 
(F3,38=8.82, p=0.005). The differences in myo-inositol levels were particularly large: in CHR-T 263 
subjects, the concentration was 21.8% higher than in CHR-NT subjects (effect size 1.01), 264 
and 22.8% higher than in HCs (effect size 0.98). In contrast, there were no significant 265 
differences between CHR-NT subjects and HCs in the levels of any hippocampal metabolite 266 
(Figure 2).  267 
 268 
Functional outcome  269 
CHR subjects with a poor functional outcome had significantly higher glutamate levels 270 
than those with a good outcome (F3,52 =6.39, p = 0.015; effect size 0.75). There were no 271 
other significant differences in metabolite levels. None of the metabolite levels were 272 
significantly different between either of the CHR functional outcome subgroups and the HCs 273 
(Figure 3).   274 
 275 
Prediction of outcome  276 
Results from logistic regression analyses showed that hippocampal glutamate levels 277 
significantly predicted clinical outcome, both in terms of transition/non-transition to psychosis 278 
(β=0.48, OR=1.61, p=0.05) and overall functioning (β=0.53, OR=1.71, p=0.02).   279 
 280 
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All CHRs vs Healthy controls 281 
There were no significant group differences in any of the metabolite concentrations 282 
between the total CHR group (independent of outcomes) and HCs (Table 2).   283 
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Discussion 284 
To our knowledge, this is the largest 1H-MRS study of metabolite levels in CHR subjects 285 
conducted to date. The overall finding was that adverse clinical outcomes in these subjects 286 
were associated with increases in hippocampal glutamate levels, as well as in the levels of a 287 
number of other metabolites. Thus, the subsequent onset of psychosis was linked to higher 288 
baseline levels of glutamate, myo-inositol, and creatine at first clinical presentation, while a 289 
low level of functioning at follow up was associated with increased glutamate levels. In 290 
contrast to the differences within the CHR group, there were no differences in metabolite 291 
levels between the total CHR sample and healthy controls, or between CHR subjects who 292 
did not have adverse clinical outcomes and controls.  293 
In line with our main hypothesis, increased hippocampal glutamate levels at baseline 294 
were associated with adverse clinical outcomes at follow up: both the onset of psychosis and 295 
a low level of overall functioning. These observations are consistent with preclinical and 296 
human data implicating hippocampal dysfunction and glutamate transmission in the onset of 297 
psychosis. In preclinical models, neural hyperactivity of the hippocampus drives an increase 298 
in subcortical dopamine activity through glutamatergic projections to the striatum.1,2 299 
Neuroimaging data from CHR samples indicate that the subgroup of subjects who 300 
subsequently develop psychosis have increased resting hippocampal metabolism3 and 301 
perfusion,4 altered hippocampal response to cognitive tasks,5 and smaller hippocampal 302 
volumes.3,6,7 As previously suggested by experimental work in rodents,3 one possibility is 303 
that these alterations are secondary to increases in hippocampal glutamate levels. 304 
Consistent with data from previous 1H-MRS studies,18-20 there were no differences in 305 
hippocampal glutamate levels between the CHR-NT or total CHR group (independent of 306 
clinical outcomes) and controls. This is also in line with previous studies using other 307 
neuroimaging modalities, which showed differences within the CHR group rather than 308 
between the total CHR group and controls in terms of hippocampal volume,7 brain activity 309 
patterns,5 and dopamine synthesis capacity.34 However, adverse clinical outcomes in CHR 310 
subjects have been linked to altered glutamate metabolite levels in other brain regions. De la 311 
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Fuente Sandoval and colleagues demonstrated increased baseline glutamate levels in the 312 
striatum of those CHR subjects who went on to develop a first episode of psychosis.21 Allen 313 
et al found that a poor functional outcome in CHR subjects was linked to lower glutamate 314 
concentrations in the thalamus at baseline,22 while Egerton and colleagues reported that 315 
lower thalamic glutamate levels were associated with a failure to achieve symptomatic 316 
remission from the CHR state.23  317 
Our second main finding was that adverse clinical outcomes were also associated with 318 
elevations in the levels of myo-inositol and creatine in the hippocampus. For both these 319 
metabolites and for glutamate, the pattern of group differences was strikingly similar, with 320 
higher levels in CHR subjects who developed psychosis relative to those who did not 321 
become psychotic (Figure 2). This consistent pattern across different metabolites suggests 322 
that the onset of psychosis was associated with a more general increase in hippocampal 323 
metabolite levels, as opposed to a change that was specific to glutamate. Such a 324 
widespread change in metabolites is consistent with previous evidence that the subsequent 325 
onset of psychosis in CHR subjects is linked to an overall change in hippocampal integrity, 326 
as indicated by hypermetabolism,3 increased resting perfusion,4 and reduced grey matter 327 
volume.3,6,7 Although previous 1H-MRS studies in CHR subjects have not reported 328 
associations between clinical outcomes and changes across multiple metabolites, higher 329 
levels of glutamate, myo-inositol and choline have been described in the striatum in 330 
medication-naïve first episode patients relative to controls.35,36  331 
In the present study, the elevation in myo-inositol levels was relatively large, with 332 
concentrations around 22% higher (and effect sizes around 1.0) in the CHR subjects who 333 
developed psychosis than in both those who did not and healthy controls. Myo-inositol is 334 
regarded as a marker for glial activation,37 and independent data from PET studies of glial 335 
activity have reported that this is increased in the hippocampus (and in other regions) in both 336 
CHR subjects and in patients with psychosis.38-40 1H-MRS studies of myo-inositol and 337 
creatine levels in the hippocampus in patients with chronic psychosis have not found a 338 
consistent pattern of differences in comparison to controls.41-44 However, inconsistencies in 339 
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1H-MRS findings in patients with chronic psychosis may be related to confounding effects of 340 
age, duration of illness and treatment,17 and alterations in metabolite levels may be more 341 
marked in the early than the later stages of the disorder.17,45   342 
Because the number of CHR subjects that went on to develop psychosis was modest 343 
(n=12), we cannot exclude the possibility that additional findings were undetected because 344 
of limited statistical power. This issue could be addressed by studying larger CHR samples, 345 
which can be achieved by combining 1H-MRS data from multiple centres.46 Although the 346 
mean time of clinical follow up was 18.5 months, the variance in duration of follow up 347 
intervals was fairly high (range 4 - 59 months). The main reason for this was that follow up 348 
times were not a priori defined. Importantly, a recent study of transitions in our early 349 
intervention service showed that about 60% of the transitions occurred in the first 18 months, 350 
with the rate strongly decreasing thereafter.47 Our findings could be confounded by effects of 351 
antipsychotic treatment. This is unlikely, however, because the vast majority of the CHR 352 
subjects (72/86) were naive to antipsychotic drugs, and if treated, low doses of 353 
antipsychotics were prescribed. Moreover, there were no significant differences between 354 
medicated and unmedicated CHR subjects for any of the hippocampal metabolites. Residual 355 
effects of illicit substance use cannot be excluded because this was checked by self-report 356 
rather than by urine toxicology screening. Given the dimensions and orientation of our 1H-357 
MRS voxel, other medial temporal lobe regions than the hippocampus, such as the 358 
parahippocampal gyrus, are also included in the voxel, which may have confounded our 359 
results. Consequently, although 1H-MRS values were corrected for CSF volume, we cannot 360 
exclude the possibility that increased metabolite concentrations are related to changes in 361 
hippocampal volume. Finally, using conventional 1H-MRS, it is not possible to determine 362 
whether differences in glutamate levels are related to neurotransmission or metabolism, an 363 
issue which may be addressed by using more sophisticated MRS protocols.48  364 
In conclusion, our study suggests that clinical outcomes in people at CHR for psychosis 365 
are related to baseline hippocampal metabolite concentrations. While the findings require 366 
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replication, they raise the possibility that measuring hippocampal metabolite levels could 367 
contribute to the stratification of CHR subjects according to future clinical outcomes.  368 
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Figure Legends 538 
 539 
Figure 1. Example of 1H-MRS voxel placement and spectrum. 540 
Example of 1H-MRS voxel placement in the left hippocampus (left), and 1H-MRS spectrum 541 
obtained from this voxel (black line) and the overlay of the spectral fit (red line) (right).  542 
 543 
Figure 2. Hippocampal metabolite concentrations and the transition to psychosis. 544 
Left hippocampal metabolite concentrations in healthy controls (HC; n=30), clinical high risk 545 
subjects who did not make a transition to psychosis (CHR-NT; n=74), and clinical high risk 546 
subjects who made a transition to psychosis (CHR-T; n=12). At first presentation, the CHR-T 547 
subgroup showed significantly higher hippocampal levels of glutamate, myo-inositol and 548 
creatine than the CHR-NT subgroup, and higher concentrations of myo-inositol than HCs. 549 
Glx, combined measure of glutamine and glutamate; NAA, N-acetylaspartate. * Significant 550 
difference between groups.     551 
 552 
Figure 3. Hippocampal metabolite concentrations and functional outcome. 553 
Left hippocampal metabolite concentrations in healthy controls (HC; n=30), clinical high risk 554 
subjects with a good functional outcome (CHR-GO; n=19), and clinical high risk subjects 555 
with a poor functional outcome (CHR-PO; n=38). At first presentation, the CHR-PO 556 
subgroup showed significantly higher hippocampal glutamate levels than the CHR-GO 557 
subgroup. Glx, combined measure of glutamine and glutamate; NAA, N-acetylaspartate. * 558 
Significant difference between groups.     559 
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Table 1 Baseline demographic, clinical and medication data. 560 
Measure HC  
N=30 
CHR  
N=86 
p  CHR-NT 
N=74 
CHR-T 
N=12 
p CHR-GO 
N=19 
CHR-PO 
N=38 
p 
Age (years) 24.7 (3.8) 22.4 (3.5) 0.005 22.5 (3.7) 22.1 (2.8) 0.71 22.1 (3.3) 23.3 (3.9) 0.24 
NART IQ 104.8 (13.6) 103.9 (12.2) 0.75 104.7 (12.0) 99.3 (12.5) 0.17 106.3 (9.2) 105.2 (13.3)  0.76 
Years of education  15.8 (3.3) 14.5 (2.2) 0.021 14.6 (2.1) 14.3 (2.5) 0.71 14.8 (2.3) 14.3 (2.1) 0.45 
CAARMS          
Positive score _ 10.2 (4.2) _ 10.0 (4.4) 11.3 (3.3) 0.33 10.2 (4.2) 10.5 (4.3)  0.75 
Negative score _ 5.5 (4.2) _ 5.4 (4.1) 6.1 (4.9) 0.63 6.4 (3.9) 5.5 (4.3) 0.44 
Total score _ 43.6 (21.8) _ 42.8 (21.7) 48.9 (22.9) 0.39 45.5 (19.9) 42.7 (20.8) 0.63 
Baseline GAF score 93.0 (5.1) 57.7 (9.4) <0.001 58.4 (9.5) 53.6 (7.6) 0.11 56.8 (8.9) 54.8 (9.6) 0.48 
HAM-A score 3.6 (4.2) 18.4 (11.0) <0.001 17.1 (10.3) 27.3 (12.1) 0.01 18.3 (12.8) 20.6 (11.8) 0.57 
HAM-D score 1.7 (3.6) 17.4 (11.0) <0.001 16.4 (11.1) 24.4 (8.2) 0.05 15.5 (10.3) 19.6 (11.9) 0.28 
Tobacco (cigarettes/day) 1.9 (3.3) 5.5 (8.5) 0.024 6.1 (8.9) 1.83 (3.6) 0.11 6.7 (10.0) 5.7 (8.5) 0.70 
Alcohol (units/day) 1.6 (2.2) 1.5 (3.1) 0.82 1.6 (3.4)  0.83 (0.72) 0.44 1.4 (1.0) 1.5 (4.0) 0.91 
Cannabis (median)a 0 0 0.71 0 0 0.81 1  0 0.18 
          
27 
 
 N (%) N (%) p N (%) N (%) p N (%) N (%) p 
Antipsychotic medication 0 (0) 10 (12) _ 10 (13)  1 (0.08) 0.63 3 (16) 2 (5) 0.19 
Male 14 (47) 50 (58) 0.28 43 (58) 7 (58) 0.95 9 (47)  23 (61) 0.35 
Right-handed  27 (90) 70 (81) 0.13 60 (80) 11 (92)  0.33 17 (90) 29 (76) 0.24 
a 0=never, 1=experimental use, 2=occasional use, 3=moderate use, 4=severe use.  561 
CAARMS, Comprehensive Assessment for the At-Risk Mental State; CHR, clinical high risk; CHR-GO, clinical high risk good outcome; CHR-562 
NT, clinical high risk non-transition; CHR-PO, clinical high risk poor outcome; CHR-T, clinical high risk transition; GAF, Global Assessment of 563 
Functioning scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy controls; NART, National 564 
Adult Reading Test.  565 
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Table 2 Mean (SD) hippocampal metabolite levels in healthy controls (HC; n=30) and clinical 566 
high risk subjects (CHR; n=86).  567 
 HC 
N=30 
CHR 
N=86 
Analysis 
F p 
Glutamate 8.31 (1.12) 8.45 (1.48) 0.49 0.48 
Glx  11.61 (2.23) 11.57 (2.45) 0.01 0.92 
Myo-inositol 6.19 (1.51) 6.43 (1.42) 2.11 0.15 
Creatine 7.42 (1.10) 7.43 (1.08) 0.20 0.66 
Choline 2.30 (0.40) 2.41 (0.42) 1.95 0.17 
NAA 9.34 (1.43) 9.36 (1.13) 0.002 0.97 
CHR, clinical high risk; Glx, combined measure of glutamine and glutamate; HC, healthy 568 
controls; NAA, N-acetylaspartate. 569 
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Metabolite
HC
N=30
CHR-NT
N=74
CHR-T
N=12
CHR-NT vs CHR-T CHR-T vs HC CHR-NT vs HC
p (effect size) p (effect size) p (effect size) 
Glutamate 8.31 (1.12) 8.33 (1.48) 9.16 (1.28) 0.048 (0.57) 0.07 (0.73) 0.70 (0.01)
Glx 11.61 (2.23) 11.43 (2.48) 12.44 (2.16) 0.18 (0.41) 0.32 (0.38) 0.89 (0.07)
Myo-Inositol 6.19 (1.51) 6.24 (1.36) 7.60 (1.23) 0.002 (1.01) 0.005 (0.98) 0.43 (0.04)
Crea!ne 7.42 (1.10) 7.32 (1.09) 8.18 (0.74) 0.009 (0.82) 0.035 (0.75) 0.90 (0.09)
Choline 2.30 (0.40) 2.40 (0.43) 2.59 (0.21) 0.06 (0.47) 0.020 (0.81) 0.35 (0.23)
NAA 9.34 (1.43) 9.34 (1.18) 9.49 (0.80) 0.63 (0.13) 0.66 (0.12) 0.92 (0.07)
Metabolite
HC
N=30
CHR-GO
N=19
CHR-PO
N=38
CHR-GO vs CHR-PO CHR-PO vs HC CHR-GO vs HC
p (effect size) p (effect size) p (effect size) 
Glutamate 8.31 (1.12) 7.76 (1.40) 8.83 (1.43) 0.015 (0.75) 0.19 (0.40) 0.35 (0.45)
Glx 11.61 (2.23) 10.78 (2.11) 11.90 (2.38) 0.09 (0.49) 0.59 (0.13) 0.21 (0.38)
Myo-Inositol 6.19 (1.51) 6.37 (1.70) 6.39 (1.17) 0.80 (0.01) 0.36 (0.15) 0.35 (0.11)
Crea!ne 7.42 (1.10) 7.01 (1.31) 7.63 (1.18) 0.08 (0.51) 0.55 (0.18) 0.62 (0.35)
Choline 2.30 (0.40) 2.36 (0.56) 2.40 (0.37) 0.90 (0.09) 0.48 (0.26) 0.28 (0.13)
NAA 9.34 (1.43) 8.84 (0.97) 9.28 (1.06) 0.16 (0.43) 0.65 (0.05) 0.41 (0.39)
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